7岁儿童隐蔽性高铁血红蛋白血症及儿科急诊药师干预的机会

Q2 Medicine
Kendra L Walsh, Christian R Silva, Patrick H Lee
{"title":"7岁儿童隐蔽性高铁血红蛋白血症及儿科急诊药师干预的机会","authors":"Kendra L Walsh, Christian R Silva, Patrick H Lee","doi":"10.5863/1551-6776-29.6.650","DOIUrl":null,"url":null,"abstract":"<p><p>Methemoglobinemia is a rare, yet life-threatening disorder that occurs due to an accumulation of methemoglobin in the blood. The clinical presentation often includes dyspnea, cyanosis, and hypoxemia that shows little improvement with the administration of supplemental oxygen. The US Food and Drug Administration (FDA) warns against the administration of benzocaine to those younger than 2 years of age and urges manufacturers to add a statement regarding the possible development of methemoglobinemia to the packaging of any products containing this ingredient. However, providers caring for pediatric patients should recognize that methemoglobinemia may occur in toddlers and children outside of the FDA's specific age warning window and must keep a broad differential for patients presenting with respiratory distress. The objective of this article is to highlight a case of a child subsequently found to have benzocaine-induced methemoglobinemia and emphasize the importance of pharmacists in an emergency medicine setting, particularly in the care of patients with uncommon acute conditions requiring lesser-known pharmacologic treatments.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"29 6","pages":"650-653"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627564/pdf/","citationCount":"0","resultStr":"{\"title\":\"Occult Methemoglobinemia in a Medically-Complex 7-Year-Old Child and the Opportunity for Pharmacist Intervention in Pediatric Emergency Medicine.\",\"authors\":\"Kendra L Walsh, Christian R Silva, Patrick H Lee\",\"doi\":\"10.5863/1551-6776-29.6.650\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Methemoglobinemia is a rare, yet life-threatening disorder that occurs due to an accumulation of methemoglobin in the blood. The clinical presentation often includes dyspnea, cyanosis, and hypoxemia that shows little improvement with the administration of supplemental oxygen. The US Food and Drug Administration (FDA) warns against the administration of benzocaine to those younger than 2 years of age and urges manufacturers to add a statement regarding the possible development of methemoglobinemia to the packaging of any products containing this ingredient. However, providers caring for pediatric patients should recognize that methemoglobinemia may occur in toddlers and children outside of the FDA's specific age warning window and must keep a broad differential for patients presenting with respiratory distress. The objective of this article is to highlight a case of a child subsequently found to have benzocaine-induced methemoglobinemia and emphasize the importance of pharmacists in an emergency medicine setting, particularly in the care of patients with uncommon acute conditions requiring lesser-known pharmacologic treatments.</p>\",\"PeriodicalId\":37484,\"journal\":{\"name\":\"Journal of Pediatric Pharmacology and Therapeutics\",\"volume\":\"29 6\",\"pages\":\"650-653\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627564/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatric Pharmacology and Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5863/1551-6776-29.6.650\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5863/1551-6776-29.6.650","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

高铁血红蛋白血症是一种罕见的,但危及生命的疾病,发生由于高铁血红蛋白在血液中的积累。临床表现通常包括呼吸困难,紫绀和低氧血症,在补充氧气的情况下几乎没有改善。美国食品和药物管理局(FDA)警告2岁以下儿童不要服用苯佐卡因,并敦促制造商在含有该成分的任何产品的包装上添加关于可能导致高铁血红蛋白血症的声明。然而,照顾儿科患者的提供者应该认识到,高铁血红蛋白血症可能发生在婴幼儿和FDA特定年龄警告窗口之外的儿童中,并且必须对出现呼吸窘迫的患者保持广泛的区分。本文的目的是强调一个儿童随后被发现患有苯佐卡因引起的高铁血红蛋白血症的病例,并强调药剂师在急诊医学环境中的重要性,特别是在照顾那些需要鲜为人知的药物治疗的罕见急性疾病的患者时。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Occult Methemoglobinemia in a Medically-Complex 7-Year-Old Child and the Opportunity for Pharmacist Intervention in Pediatric Emergency Medicine.

Methemoglobinemia is a rare, yet life-threatening disorder that occurs due to an accumulation of methemoglobin in the blood. The clinical presentation often includes dyspnea, cyanosis, and hypoxemia that shows little improvement with the administration of supplemental oxygen. The US Food and Drug Administration (FDA) warns against the administration of benzocaine to those younger than 2 years of age and urges manufacturers to add a statement regarding the possible development of methemoglobinemia to the packaging of any products containing this ingredient. However, providers caring for pediatric patients should recognize that methemoglobinemia may occur in toddlers and children outside of the FDA's specific age warning window and must keep a broad differential for patients presenting with respiratory distress. The objective of this article is to highlight a case of a child subsequently found to have benzocaine-induced methemoglobinemia and emphasize the importance of pharmacists in an emergency medicine setting, particularly in the care of patients with uncommon acute conditions requiring lesser-known pharmacologic treatments.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pediatric Pharmacology and Therapeutics
Journal of Pediatric Pharmacology and Therapeutics Medicine-Pediatrics, Perinatology and Child Health
CiteScore
2.40
自引率
0.00%
发文量
90
期刊介绍: The Journal of Pediatric Pharmacology and Therapeutics is the official journal of the Pediatric Pharmacy Advocacy Group. JPPT is a peer-reviewed multi disciplinary journal that is devoted to promoting the safe and effective use of medications in infants and children. To this end, the journal publishes practical information for all practitioners who provide care to pediatric patients. Each issue includes review articles, original clinical investigations, case reports, editorials, and other information relevant to pediatric medication therapy. The Journal focuses all work on issues related to the practice of pediatric pharmacology and therapeutics. The scope of content includes pharmacotherapy, extemporaneous compounding, dosing, methods of medication administration, medication error prevention, and legislative issues. The Journal will contain original research, review articles, short subjects, case reports, clinical investigations, editorials, and news from such organizations as the Pediatric Pharmacy Advocacy Group, the FDA, the American Academy of Pediatrics, the American Society of Health-System Pharmacists, and so on.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信